Original Article

Journal of Investigative Dermatology (1996) 107, 856–859; doi:10.1111/1523-1747.ep12331160

IL-4 Upregulates Tenascin Synthesis in Scleroderma and Healthy Skin Fibroblasts

Huda A Makhluf, Joanna Stepniakowska, Stanley Hoffman, Edwin Smith, E Carwile LeRoy and Maria Trojanowska

Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina, U.S.A.

Received 1 May 1996; Revised 1 July 1996; Accepted 22 July 1996.

Top

Abstract

Tenascin (TN), a large extracellular matrix glycoprotein, is transiently expressed during embryonic development, but is absent from most normal adult tissues. TN is reexpressed, however, in healing wounds, in the stroma of some tumors, and in fibrotic diseases such as systemic sclerosis (SSc) and rheumatoid arthritis. To clarify the mechanisms regulating TN expression, we studied the effects of selected cytokines (PDGF, bFGF, TGF-beta, IL-1, IL-4, IL-6, IFN-gamma, and TNF-alpha) found in fibrotic tissue on TN expression by dermal fibroblasts. IL-4 strongly induced TN protein levels (up to 10-fold over the basal level), whereas PDGF and bFGF were less potent inducers of TN than IL-4. All other cytokines tested, including TGF-beta, did not stimulate TN synthesis IL-4 also increased TN mRNA expression, and this effect was blocked by actinomycin D. Cycloheximide increased basal TN mRNA expression and induced TN mRNA in IL-4-treated fibroblasts, suggesting that repressor protein(s) may regulate transcription of the TN gene. Although no differences in constitutive TN expression or effects of cytokines on TN expression were observed between SSc and healthy fibroblasts, these data are consistent with the observations that high levels of both LL-4 and TN are present in the affected skin of patients with SSc. These results suggest that the high level of TN found in the affected tissue of patients with SSc results from the high level of IL-4 present.

Keywords:

bFGF, PDGF, TGFbeta

Top

References

  1. Chiquet-Ehrismann, R, Kalla, P, Pearson, CA: Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res 49: 4322–4325, 1989 | PubMed | ChemPort |
  2. Claman, HN: On scleroderma. Mast cells, endothelial cells, and fibroblasts. JAMA 262: 1206–1209, 1989 | Article | PubMed | ChemPort |
  3. Erickson, HP, Bourdon, MA: Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Anna Rev Cell Biol 5: 71–92, 1989
  4. Fagundus, DM, LeRoy, EC: Cytokines and systemic sclerosis. Clin Dermatol 12: 407–417, 1994 | PubMed | ISI | ChemPort |
  5. Gailit, J, Clark, RA: Wound repair in the context of extracellular matrix. Curr Opin Cell Biol 6: 717–725, 1994 | Article | PubMed | ISI | ChemPort |
  6. Gruber, BL: Mast cells: accessory cells which potentiate fibrosis. Int Rev Immunol 12: 259–279, 1995
  7. Koukoulis, GK, Gould, VE, Bhattacharyya, A, Gould, JE, Howeedy, AA, Virtanen, I: Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol 22: 636–643, 1991 | Article | PubMed | ISI | ChemPort |
  8. La Fleur, DW, Fagin, JA, Forrester, JS, Rubin, SA, Sharifi, BG: Cloning and character-ization of alternatively spliced isoforms of rat tenascin. Platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. J BM Chem 269: 20757–20763, 1994
  9. Lacour, JP, Vitetta, A, Chiquet-Ehrismann, R, Pisani, A, Ortonne, JP: Increased expression of tenascin in the dermis in scleroderma. Br J Dermatol 127: 328–334, 1992 | PubMed | ISI | ChemPort |
  10. Lightner, VA, Gumkowski, F, Bigtter, DD, Erickson, HP: Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy. J Cell Biol 108: 2483–2493, 1989
  11. McCachren, SS, Lightner, VA: Expression of human tenascin in synovitis and its regulation by interleukin-1. Arthritis Rheum 35: 1185–1196, 1992 | PubMed | ISI | ChemPort |
  12. Needleman, BW, Wigley, FM, Stair, RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 35: 67–72, 1992 | PubMed | ISI | ChemPort |
  13. Pearson, CA, Pearson, D, Shibahara, S, Hofsteenge, J, Chiquet-Ehrismann, R: Tenascin: cDNA cloning and induction by TGF-beta. EMBO J 7: 2977–2982, 1988 | PubMed | ChemPort |
  14. Rettig, WJ, Erickson, HP, Albino, AP, Garin-Chesa, P: Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways. J Cell Sci 107: 487–497, 1994 | PubMed | ISI | ChemPort |
  15. Rettig, WJ, Garin-Chesa, P: Cell type-specific control of human neuronectin secretion by polypeptide mediators and phorbol ester. J Histochem Cytochem 37: 1777–1786, 1989 | PubMed | ISI | ChemPort |
  16. Salter, DM: Tenascin is increased in cartilage and synovium from arthritic knees. Br J Rheumatol 132: 780–786, 1993
  17. Sharifi, BG, La Fleur, DW, Pirola, CJ, Forrester, JS, Fagin, JA: Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. J Biol Chem 267: 23910–23915, 1992 | PubMed |
  18. Tucker, RP, Hammarback, JA, Jenrath, DA, Mackie, EJ, Xu, Y: Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. J Cell Sci 104: 69–76, 1993 | PubMed |
  19. Whitby, DJ, Ferguson, MW: The extracellular matrix of lip wounds in fetal, neonatal and adult mice. Development 112: 651–668, 1991 | PubMed | ISI | ChemPort |
  20. Yamakage, A, Kikuchi, K, Smith, EA, LeRoy, EC, Trojanowska, M: Selective upregulation of platelet-derived growth factor a receptors by transforming growth factor B in scleroderma fibroblasts. J Exp Med 175: 1227–1234, 1992 | Article | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT